tiprankstipranks
Biotron Limited (BITRF)
OTHER OTC:BITRF
Holding BITRF?
Track your performance easily

Biotron Limited (BITRF) Stock Price & Analysis

10 Followers

BITRF Stock Chart & Stats


Financials

Annual

BITRF FAQ

What was Biotron Limited’s price range in the past 12 months?
Biotron Limited lowest stock price was <$0.01 and its highest was $0.08 in the past 12 months.
    What is Biotron Limited’s market cap?
    Currently, no data Available
    When is Biotron Limited’s upcoming earnings report date?
    Biotron Limited’s upcoming earnings report date is Feb 19, 2025 which is in 86 days.
      How were Biotron Limited’s earnings last quarter?
      Biotron Limited released its earnings results on Aug 29, 2024. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.001.
        Is Biotron Limited overvalued?
        According to Wall Street analysts Biotron Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Biotron Limited pay dividends?
          Biotron Limited does not currently pay dividends.
          What is Biotron Limited’s EPS estimate?
          Biotron Limited’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Biotron Limited have?
          Biotron Limited has 902,342,600 shares outstanding.
            What happened to Biotron Limited’s price movement after its last earnings report?
            Biotron Limited reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Biotron Limited?
              Currently, no hedge funds are holding shares in BITRF
              ---

              Biotron Limited Stock Smart Score

              Company Description

              Biotron Limited

              Biotron Ltd is a biotechnology company. The company is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Northwest Biotherapeutics
              Inovio Pharmaceuticals
              Advaxis
              ImmunoCellular Therapeutics
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis